A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in The Netherlands
Latest Information Update: 10 Oct 2025
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms PIONEER REAL
- Sponsors Novo Nordisk
Most Recent Events
- 24 Sep 2025 Actual primary completion date changed from 1 Nov 2022 to 19 Dec 2022.
- 25 Jan 2023 Status changed from active, no longer recruiting to completed.
- 17 Nov 2022 Planned primary completion date changed from 4 Sep 2022 to 6 Dec 2022.